VYNE Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	24.03	19.93	30.67	30.98	42.86
Short-Term Investments	4.98	41.59	62.63	-	-
Cash & Short-Term Investments	29.01	61.52	93.31	30.98	42.86
Cash Growth	-52.84%	-34.07%	201.23%	-27.72%	-27.91%
Accounts Receivable	-	-	-	-	7.58
Other Receivables	-	-	-	5	-
Total Trade Receivables	-	-	-	5	7.58
Other Current Assets	1	2.92	2.66	2.3	12.75
Total Current Assets	30.01	64.44	95.96	38.28	63.19
Net Property, Plant & Equipment	0.09	0.21	0.21	-	0.35
Other Long-Term Assets	0.06	2.26	1.52	2.48	3.51
Total Assets	30.16	66.91	97.69	40.76	67.05
Accounts Payable	1.04	2.71	1.66	2.39	6.51
Accrued Expenses	1.35	10.7	5.76	6.96	11.55
Current Portion of Leases	-	0.1	0.12	-	0.35
Other Current Liabilities	-	1.31	-	-	-
Total Current Liabilities	2.4	14.82	7.54	9.35	18.41
Long-Term Leases	-	-	0.1	-	-
Other Long-Term Liabilities	-	-	1.31	-	-
Total Long-Term Liabilities	-	-	1.41	-	-
Total Liabilities	2.4	14.82	8.95	9.35	18.41
Common Stock	0	0	0	0	0.01
Additional Paid-in Capital	785.41	783.24	780.04	693.94	688.16
Accumulated Other Comprehensive Income	0	0.02	0.03	-	-
Retained Earnings	-757.65	-731.17	-691.34	-662.74	-639.53
Total Common Shareholders' Equity	27.77	52.09	88.74	31.2	48.64
Minority Interest	-	-	-	0.21	-
Shareholders' Equity	27.77	52.09	88.74	31.41	48.64
Total Liabilities & Equity	30.16	66.91	97.69	40.76	67.05
Total Debt	0	0.1	0.21	0	0.35
Net Cash (Debt)	29.01	61.42	93.09	30.98	42.51
Net Cash Growth	-52.77%	-34.03%	200.54%	-27.13%	72.36%
Net Cash Per Share	1.39	1.44	9.06	9.72	14.87
Book Value	27.77	52.09	88.74	31.2	48.64
Book Value Per Share	1.33	1.22	8.64	9.79	17.01
Tangible Book Value	27.77	52.09	88.74	31.2	48.64
Tangible Book Value Per Share	1.33	1.22	8.64	9.79	17.01

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q